Abacavir and myocardial infarctions: The benefit of doubt?

AIDS

Volumn 25, Issue 16, 2011, Pages 2043-2045

  Behrens, Georg M N ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

abacavir; antiretroviral therapy; HIV; myocardial infarction

Indexed keywords

ABACAVIR; TENOFOVIR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HUMANS; MALE;

EID: 80054991161     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834bab9e     Document Type: Editorial

References (21)

1. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-2240.
2. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-BM5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
3. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al., D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
4. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKlinesponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-28.
5. Behrens GM, Reiss P. Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010; 23:9-14.
6. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virusinfected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-1238.
7. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25:1289-1298.
8. Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a populationbased nationwide cohort study. HIV Med 2010; 11:130-136.
9. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database (RAMQ). J Acquir Immune Defic Syndr 2011; 57:245-253.
10. Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and longterm results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929-940.
11. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53:84-91.
12. Padilla S, Masiá M, Garća N, Jarrin I, Tormo C, Gutiérrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011; 11:40.
13. Mart́nez E, Larrousse M, Podzamczer D, Pérez I, Gutiérrez F, Loncá M, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24:F1-F9.
14. De Pablo C, Orden S, Apostolova N, Blanquer A, Esplugues JV, Alvarez A. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. AIDS 2010; 24:1259-1266.
15. Satchell CS, Cotter AG, O'Connor EF, Peace AJ, Tedesco AF, Clare A, et al. Platelet function and HIV: a case-control study. AIDS 2010; 24:649-657.
16. Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, et al. ABACAVIR use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011; 25:1993-2004.
17. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of myocardial infarction with ABC use: an FDA meta-analysis. In: CROI; 2011; Boston, Massachusetts, USA.
18. Costagliola D, Lang S, Mary-Krause M, Boccara F. Abacavir and cardiovascular risk: reviewing the evidence. Curr HIV/AIDS Rep 2010; 7:127-133.
19. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011; 8:e1001026.
20. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-456.
21. Boccara F, Mary-Krause M, Teiger E, Lang S, Lim P, Wahbi K, et al., Prognosis of Acute Coronary Syndrome in HIV-infected patients (PACS) Investigators. Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. Eur Heart J 2011; 32:41-50.